Role of PET in the initial staging of cutaneous malignant melanoma: systematic review
- PMID: 19011184
- DOI: 10.1148/radiol.2493080240
Role of PET in the initial staging of cutaneous malignant melanoma: systematic review
Abstract
Purpose: To calculate summary estimates of the diagnostic performance of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomographic (PET) imaging in the initial staging of cutaneous malignant melanoma (CMM), following the new American Joint Committee on Cancer (AJCC) staging classification on per-patient and per-lesion bases.
Materials and methods: MEDLINE, EMBASE, Web of Science, and Cochrane Database of Systematic Reviews databases, and reference lists of reviews and included papers were searched, without any language restrictions, for relevant articles published before March 2007. Two reviewers independently assessed study eligibility and methodologic quality by using the quality assessment of diagnostic accuracy studies checklist. A pooled random effect was estimated and a fixed coefficient regression model was used to explore the existing heterogeneity.
Results: Twenty-eight studies involving 2905 patients met the inclusion criteria. The pooled estimates of FDG PET for the detection of metastasis in the initial staging of CMM were sensitivity, 83% (95% confidence interval [CI]: 81%, 84%); specificity, 85% (95% CI: 83%, 87%); positive likelihood ratio (LR), 4.56 (95% CI: 3.12, 6.64); negative LR, 0.27 (95% CI: 0.18, 0.40); and diagnostic odds ratio, 19.8 (95% CI: 10.8, 36.4). Results from eight studies suggested that FDG PET was associated with 33% disease management changes (range, 15%-64%).
Conclusion: There is good preliminary evidence that FDG PET is useful for the initial staging of patients with CMM, especially as adjunctive role in AJCC stages III and IV, to help detect deep soft-tissue, lymph node, and visceral metastases. FDG PET-computed tomographic imaging seemed to be more precise than PET alone, as suggested by four eligible studies. Further evaluation by using a well-designed prospective study, with clinical outcome-focused measures and cost effectiveness analysis, is needed to clarify the appropriate role of FDG PET in CMM staging.
Supplemental material: http://radiology.rsnajnls.org/cgi/content/full/249/3/836/DC1.
RSNA, 2008
Similar articles
-
Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients.Cancer. 2001 Apr 15;91(8):1530-42. Cancer. 2001. PMID: 11301402
-
Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma.Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):284-300. doi: 10.1007/s00259-009-1224-8. Epub 2009 Sep 2. Eur J Nucl Med Mol Imaging. 2010. PMID: 19727717 Free PMC article.
-
Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis.Surg Oncol. 2014 Mar;23(1):11-6. doi: 10.1016/j.suronc.2014.01.002. Epub 2014 Jan 26. Surg Oncol. 2014. PMID: 24556310 Review.
-
The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. doi: 10.3310/hta15350. Health Technol Assess. 2011. PMID: 21958472 Free PMC article. Review.
-
Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.Cancer. 2005 Aug 1;104(3):570-9. doi: 10.1002/cncr.21189. Cancer. 2005. PMID: 15977211
Cited by
-
Imaging malignant melanoma with (18)F-5-FPN.Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):113-122. doi: 10.1007/s00259-015-3134-2. Epub 2015 Aug 11. Eur J Nucl Med Mol Imaging. 2016. PMID: 26260649
-
FDG PET/CT in cancer: comparison of actual use with literature-based recommendations.Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):695-706. doi: 10.1007/s00259-015-3217-0. Epub 2015 Oct 30. Eur J Nucl Med Mol Imaging. 2016. PMID: 26519292 Free PMC article.
-
Intense FDG uptake in an intra-articular localized giant-cell tumor of the tendon sheath (pigmented villonodular synovitis) mimics metastatic melanoma.Radiol Case Rep. 2015 Nov 6;4(4):343. doi: 10.2484/rcr.v4i4.343. eCollection 2009. Radiol Case Rep. 2015. PMID: 27307839 Free PMC article.
-
Melanoma and nuclear medicine.Melanoma Manag. 2014 Aug;1(1):57-74. doi: 10.2217/mmt.14.10. Epub 2014 Sep 5. Melanoma Manag. 2014. PMID: 30190811 Free PMC article. Review.
-
FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973.EJNMMI Res. 2012 May 31;2(1):22. doi: 10.1186/2191-219X-2-22. EJNMMI Res. 2012. PMID: 22651703 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous